PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
1.52 - 1.58
1.19 - 3.37
354.5K / 984.1K (Avg.)
-1.64 | -0.94
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-0.34%
Negative revenue growth while CSIQ stands at 2.26%. Joel Greenblatt would look for strategic missteps or cyclical reasons.
105.72%
Gross profit growth 1.25-1.5x CSIQ's 83.62%. Bruce Berkowitz would see if strategic sourcing or brand premium explains outperformance.
57.70%
EBIT growth below 50% of CSIQ's 976.88%. Michael Burry would suspect deeper competitive or cost structure issues.
46.08%
Operating income growth under 50% of CSIQ's 3692.84%. Michael Burry would be concerned about deeper cost or sales issues.
30.28%
Net income growth under 50% of CSIQ's 386.55%. Michael Burry would suspect the firm is falling well behind a key competitor.
30.93%
EPS growth under 50% of CSIQ's 386.96%. Michael Burry would suspect deeper structural issues or share dilution limiting per-share gains.
30.93%
Diluted EPS growth under 50% of CSIQ's 373.91%. Michael Burry would worry about an eroding competitive position or excessive dilution.
0.39%
Share count expansion well above CSIQ's 0.20%. Michael Burry would question if management is raising capital unnecessarily or is over-incentivizing employees with stock.
0.39%
Diluted share reduction more than 1.5x CSIQ's 7.29%. David Dodd would validate if the company is aggressively retiring shares or limiting option exercises.
No Data
No Data available this quarter, please select a different quarter.
-27.51%
Negative OCF growth while CSIQ is at 0.00%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.
-15.58%
Negative FCF growth while CSIQ is at 0.00%. Joel Greenblatt would demand improved cost control or more strategic capex discipline.
1.68%
10Y revenue/share CAGR under 50% of CSIQ's 439.47%. Michael Burry would suspect a lasting competitive disadvantage.
-53.23%
Negative 5Y CAGR while CSIQ stands at 48.09%. Joel Greenblatt would push for a turnaround plan or reevaluation of the company’s product line.
-39.91%
Negative 3Y CAGR while CSIQ stands at 5.00%. Joel Greenblatt would look for missteps or fading competitiveness that hurt sales.
-1801.75%
Negative 10Y OCF/share CAGR while CSIQ stands at 0.00%. Joel Greenblatt would scrutinize managerial effectiveness and product competitiveness.
-208.25%
Negative 5Y OCF/share CAGR while CSIQ is at 0.00%. Joel Greenblatt would question the firm’s operational model or cost structure.
-14.01%
Negative 3Y OCF/share CAGR while CSIQ stands at 0.00%. Joel Greenblatt would demand an urgent turnaround in the firm’s cost or revenue drivers.
-845.00%
Negative 10Y net income/share CAGR while CSIQ is at 726.51%. Joel Greenblatt sees a major red flag in long-term profit erosion.
5.36%
Below 50% of CSIQ's 211.73%. Michael Burry would worry about a substantial lag vs. the competitor’s profit ramp-up.
-718.62%
Both companies show negative 3Y net income/share growth. Martin Whitman suspects macro or sector-specific headwinds in the short run.
-38.05%
Negative equity/share CAGR over 10 years while CSIQ stands at 289.87%. Joel Greenblatt sees a fundamental red flag unless the competitor also struggles.
-45.43%
Negative 5Y equity/share growth while CSIQ is at 60.05%. Joel Greenblatt sees the competitor building net worth while this firm loses ground.
-48.50%
Negative 3Y equity/share growth while CSIQ is at 56.60%. Joel Greenblatt demands an urgent fix in capital structure or profitability vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
5.87%
Our AR growth while CSIQ is cutting. John Neff questions if the competitor outperforms in collections or if we’re pushing credit to maintain sales.
3.93%
Inventory growth well above CSIQ's 3.15%. Michael Burry suspects overshooting production or weaker sell-through vs. the competitor.
0.70%
Asset growth well under 50% of CSIQ's 5.12%. Michael Burry sees the competitor as far more aggressive in building resources or capacity.
-5.90%
We have a declining book value while CSIQ shows 5.95%. Joel Greenblatt sees a fundamental disadvantage in net worth creation vs. the competitor.
-9.60%
We’re deleveraging while CSIQ stands at 2.85%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
-3.71%
Our R&D shrinks while CSIQ invests at 30.12%. Joel Greenblatt checks if we risk falling behind a competitor’s new product pipeline.
1.93%
SG&A growth well above CSIQ's 3.67%. Michael Burry sees potential margin erosion unless it translates into higher sales or brand equity.